Fosmicin Side Effects

Shock: Rarely, shock symptoms may occur, so sufficient observation is needed. When such symptoms as chest anxiety, dyspnea, blood pressure decreased, cyanosis, urticaria and discomfort, etc., occur, administration should be discontinued and suitable countermeasures should be taken.
Liver: Occasionally, liver disorders such as rises in the values for SGOT, SGPT, ALP, LDH, γ-GTP, bilirubin, etc., may appear. Rarely, jaundice may appear, so sufficient observation is needed. When such symptom appears, discontinue the drug and take suitable countermeasures.
Hematological Disorders: Rarely, agranulocytosis, granulocytopenia, anemia, eosinophilia, etc., may appear.
Kidney: Renal disorders, edema, an elevated BUN value, proteinuria, abnormality in electrolytes, etc., may rarely appear.
Gastrointestinal Tract (Digestive Tract): Such side effects as stomatitis, nausea, vomiting, abdominal pain, diarrhea and anorexia may occasionally appear.
Skin: Rarely, eruption, erythema, urticaria, a feeling of itching, etc., may appear.
Respiratory Organs: A cough and asthma attacks may rarely appear.
Central and Peripheral Nervous Systems: Occasionally, patients may experience headache and a feeling of numbness of the lips following the use of this drug. Moreover, in the case of administration of large doses, spasms may occasionally appear.
Injection Site: Rarely, phlebitis develops, and angialgia may occasionally appear.
Others: Rarely, headache, oral dryness, redness, fever, feeling of fatigue, chest discomfort, a feeling of pressure on the chest, palpitation, etc., may appear.
Clinically significant adverse reactions: Shock or anaphylaxis (<0.1%) may occur. Patients should be carefully monitored and if any symptoms such as distressed feeling of chest, dyspnea, decreased blood pressure, cyanosis, urticaria or feeling unwell occur, administration should be discontinued and appropriate measures should be taken.
Serious colitis with bloody stool such as pseudomembranous colitis (<0.1%) may occur. Patients should be carefully monitored and if abdominal pain or frequent diarrhea occurs, administration should be discontinued immediately and appropriate measures should be taken.
Pancytopenia, agranulocytosis or thrombocytopenia (<0.1%) may occur. Patients should be carefully monitored and if any abnormality is observed, administration should be discontinued and appropriate measures should be taken.
Hepatic function disorder or jaundice (<0.1%) may occur. Patients should be carefully monitored and if any abnormality is observed, appropriate measures such as discontinuation or administration should be taken.
Convulsion (incidence unknown) may occur. If such a symptom is observed, administration should be discontinued and appropriate measures should be taken.
Other adverse reactions: See Table 5.

Click on icon to see table/diagram/image